|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Medifast insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Medifast insider buys are important for investors to follow.
Date | Insider | Price | Amount |
11-7-2023 Insider Buy |
Scott Schlackman Director |
$68.89
CAGR »
|
$3,626.78 53 shares |
11-7-2023 Insider Buy |
Michael A. Hoer Director |
$68.89
CAGR »
|
$3,428.24 50 shares |
11-7-2023 Insider Buy |
Andrea B. Thomas Director |
$68.89
CAGR »
|
$3,471.16 50 shares |
8-8-2023 Insider Buy |
Andrea B. Thomas Director |
$89.42
CAGR »
|
$3,408.24 38 shares |
8-8-2023 Insider Buy |
Scott Schlackman Director |
$89.42
CAGR »
|
$3,561.06 40 shares |
8-8-2023 Insider Buy |
Michael A. Hoer Director |
$89.42
CAGR »
|
$3,366.13 38 shares |
5-9-2023 Insider Buy |
Scott Schlackman Director |
$87.50
CAGR »
|
$1,150.19 13 shares |
5-9-2023 Insider Buy |
Andrea B. Thomas Director |
$87.50
CAGR »
|
$1,133.04 13 shares |
5-9-2023 Insider Buy |
Constance J. Hallquist Director |
$87.50
CAGR »
|
$1,167.42 13 shares |
5-9-2023 Insider Buy |
Michael A. Hoer Director |
$87.50
CAGR »
|
$1,117.55 13 shares |
2-7-2023 Insider Buy |
Constance J. Hallquist Director |
$114.97
CAGR »
|
$1,143.95 10 shares |
2-7-2023 Insider Buy |
Scott Schlackman Director |
$114.97
CAGR »
|
$1,127.17 10 shares |
2-7-2023 Insider Buy |
Andrea B. Thomas Director |
$114.97
CAGR »
|
$1,110.27 10 shares |
2-7-2023 Insider Buy |
Michael A. Hoer Director |
$114.97
CAGR »
|
$1,095.09 10 shares |
8-9-2022 Insider Buy |
Jeffrey J. Brown Director |
$126.54
CAGR »
|
$498,549.10 3,940 shares |
5-6-2020 Insider Buy |
Jeffrey J. Brown Director |
$95.12
CAGR »
|
$94,889.01 998 shares |
11-9-2016 Insider Buy |
Jeffrey J. Brown Director |
$38.71
CAGR »
|
$387,100.00 10,000 shares |
11-12-2018 Insider Buy |
Michael A. Hoer Director |
$156.23
CAGR »
|
$31,246.00 200 shares |
3-14-2017 Insider Buy |
Glenn W. Welling Director |
$41.33
CAGR »
|
$706,142.85 17,084 shares |
11-15-2016 Insider Buy |
Glenn W. Welling Director |
$39.02
CAGR »
|
$1,365,567.94 35,000 shares |
8-6-2015 Insider Buy |
Glenn W. Welling Director |
$30.00
CAGR »
|
$35,970.00 1,199 shares |
Also See: Institutional Holders of MED
Also See: SEC filings
Below we present the annualized performance delivered by Medifast stock since 11-7-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Medifast insider buying occurred is the ultimate
test of whether insiders were right about MED being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/08/2023 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$65.92 |
|
End price/share: |
$26.69 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-59.51% |
|
Annualized Gain: |
-123.42% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$4,049.00 |
|
Years: |
0.48 |
|
Medifast Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Medifast insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding MED
|
|